By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
latest_posts
- 1
NASA releases new photos of interstellar comet 3I/ATLAS - 2The most effective method to Engage in Local area Making arrangements for 5G Pinnacle Establishments
- 3They died 'doing what they loved': The stories of workers in their 80s who died on the job
- 4Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- 55 Eating routine Well disposed Snacks to Keep You Fulfilled
- IDF, police arrest eleven for criminal, terror-related activity over weekend
- 19 Strange Motion pictures You Shouldn't Watch With Your Mum
- Gym tied to outbreak of obscure disease that spreads through mist
- ACA subsidies latest: Making sense of what's happening with health care after Republicans revolt, forcing a vote on funding extension
- One dead, six wounded in various crime-related shootings in Israel over the weekend
- Paul Feig loves a plot twist. Why not reboot 'Die Hard' starring a woman?
- 5 Movies That Leaving an Imprint with Inventive Innovation
- What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly
- Culinary Joys: Investigating Connoisseur Cooking at Home
